Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that short exposure to vibration causes epithelial cells to retract filopodia, concentrate actin at their edges, and increase expression of the protease calpain, suggesting a mechanism for vibration-induced pain relief.

This article reviews Vitamin D-dependent rickets Type II with a focus on alopecia as a potential diagnostic clue for this rare disorder, reporting no new clinical findings.

This study suggests that varicella-zoster virus infection in skin cells may play a role in segmental vitiligo's progression and depigmentation.

This study suggests that bioactives like Curcumin, Quercetin, and "Tulsi" may relieve chemotherapy-induced adverse drug reactions in cancer patients, potentially reducing resistance and recurrence.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

In this case report, a 34-year-old man with Graves' disease experienced the rare simultaneous occurrence of depigmented skin spots (vitiligo) and recurrent alopecia areata, highlighting the need for careful monitoring of autoimmune complications in such patients.

This study suggests that structural changes in the TRPV3 channel are linked to severe skin conditions like Olmsted syndrome, with differences observed between heat-activated and resting states.

This study found that patients with severe alopecia areata are willing to accept increased risks of serious infection, cancer, and blood clots when opting for a higher dose of ritlecitinib, valuing the potential for greater hair regrowth efficacy compared to a lower dose.

This study found that deleting β-catenin in epidermis-specific VDR knockout mice did not prevent UVB-induced skin tumors, indicating β-catenin does not compensate for VDR's role in tumor suppression.

This case report highlights a rare association between congenital triangular alopecia and vitiligo, noting that treatment with tofacitinib improved the patient's vitiligo but not the alopecia.

This study found that ruxolitinib modulated inflammatory changes and stimulated growth factor signals by blocking the JAK-STAT pathway in an in vitro model of alopecia areata.

ITK inhibitors may effectively treat alopecia areata.

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

This letter critiques a review of distant healing studies, highlighting significant methodological issues and limited evidence for its efficacy.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This research reports that arsenic trioxide achieved a complete remission rate of 87% in patients with relapsed acute promyelocytic leukemia, though its use involves manageable toxicities.

This study found that inhibiting the PI3Kδ enzyme in murine models of cutaneous chronic graft-versus-host disease (cGVHD) reduced skin scores and fibrosis, prevented pathogenic lymphoid structures, and improved survival, suggesting it as a promising therapeutic approach to address the disease's hypoxic pathophysiology.

This study found that KSR1 is necessary for v-Ha-ras-mediated skin tumor formation but not for MT-driven mammary cancer, indicating its potential as a therapeutic target in Ras/MAPK signaling-related tumors.

In this study, implantable vascularized engineered thrombi using autologous whole blood improved skin wound healing in rats by promoting robust microcapillary networks and accelerating healing processes.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

In this study using a mouse model with alopecia areata, the researchers found that ruxolitinib enhances hair regrowth by inhibiting the JAK-STAT signaling pathway, reducing inflammation and oxidative stress, and decreasing apoptosis, which supports its clinical effectiveness in treating this condition.

This study found that PRMT5 inhibitors showed potent anti-tumor activity in models of adenoid cystic carcinoma and that combining these inhibitors with lenvatinib may have additional growth-inhibitory effects.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

Biotin supplements did not significantly reduce hair loss in rats on valproic acid.

This narrative from Vijaya, a breast cancer patient, shares her personal experience with diagnosis, treatment, and support, highlighting the importance of emotional resilience and support groups.

This case report describes a 45-year-old Malian woman with Vogt-Koyanagi-Harada disease, highlighting its uncommon occurrence among individuals of African descent and detailing her treatment with prednisone and other adjunct therapies.

In this case study, a 42-year-old woman with alopecia areata, associated with Indralupta in Ayurveda, experienced significant hair regrowth and reduced symptoms after treatment with a combined Ayurvedic regimen involving internal medications and local applications, suggesting potential effectiveness in managing the condition.

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.